| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Nivolumab |
| Brand | Opdivo® |
| Indication | Is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 03/03/2016 |
| Rapid review completed | 04/04/2016 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 27/04/2016 |
| NCPE assessment completed | 12/10/2016 |
| NCPE assessment outcome | Reimbursement Not Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations September 2018
